These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9154345)

  • 21. The site of dopamine formation in rat striatum after L-dopa administration.
    Hefti F; Melamed E; Wurtman RJ
    J Pharmacol Exp Ther; 1981 Apr; 217(1):189-97. PubMed ID: 7205652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. L-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats.
    Alam M; Schmidt WJ
    Behav Brain Res; 2004 Aug; 153(2):439-46. PubMed ID: 15265640
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo neurochemical effects of the NR2B selective NMDA receptor antagonist CR 3394 in 6-hydroxydopamine lesioned rats.
    Sarre S; Lanza M; Makovec F; Artusi R; Caselli G; Michotte Y
    Eur J Pharmacol; 2008 Apr; 584(2-3):297-305. PubMed ID: 18342306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Semi-chronic increase in striatal level of 3,4-dihydroxyphenylacetaldehyde does not result in alteration of nigrostriatal dopaminergic neurones.
    Legros H; Janin F; Dourmap N; Bonnet JJ; Costentin J
    J Neurosci Res; 2004 Feb; 75(3):429-35. PubMed ID: 14743456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Different responsiveness of striatonigral and striatopallidal neurons to L-DOPA after a subchronic intermittent L-DOPA treatment.
    Carta AR; Tronci E; Pinna A; Morelli M
    Eur J Neurosci; 2005 Mar; 21(5):1196-204. PubMed ID: 15813929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serotonergic activation after 2-week intrastriatal infusion of L-dopa and slow recovery of circling in rats with unilateral nigral lesions.
    Kääriäinen TM; García-Horsman JA; Piltonen M; Huotari M; Männistö PT
    Basic Clin Pharmacol Toxicol; 2008 Mar; 102(3):300-7. PubMed ID: 17973898
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nicotine alters striatal glutamate function and decreases the apomorphine-induced contralateral rotations in 6-OHDA-lesioned rats.
    Meshul CK; Kamel D; Moore C; Kay TS; Krentz L
    Exp Neurol; 2002 May; 175(1):257-74. PubMed ID: 12009777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy.
    Eskow KL; Gupta V; Alam S; Park JY; Bishop C
    Pharmacol Biochem Behav; 2007; 87(3):306-14. PubMed ID: 17553556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo extracellular recording of striatal neurons in the awake rat following unilateral 6-hydroxydopamine lesions.
    Chen MT; Morales M; Woodward DJ; Hoffer BJ; Janak PH
    Exp Neurol; 2001 Sep; 171(1):72-83. PubMed ID: 11520122
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of intrastriatal administration of noradrenaline and l-DOPA on dyskinetic movements: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine-lesioned rats.
    Buck K; Ferger B
    Neuroscience; 2009 Mar; 159(1):16-20. PubMed ID: 19146929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
    Pérez V; Sosti V; Rubio A; Barbanoj M; Rodríguez-Alvarez J; Kulisevsky J
    Eur J Pharmacol; 2007 Dec; 576(1-3):83-90. PubMed ID: 17888901
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
    Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
    Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats.
    Yang X; Zheng R; Cai Y; Liao M; Yuan W; Liu Z
    Int J Nanomedicine; 2012; 7():2077-86. PubMed ID: 22619544
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism.
    St-Hilaire M; Landry E; Lévesque D; Rouillard C
    Neurobiol Dis; 2005 Nov; 20(2):450-60. PubMed ID: 15896973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. D2 receptor stimulation, but not D1, restores striatal equilibrium in a rat model of Parkinsonism.
    Ballion B; Frenois F; Zold CL; Chetrit J; Murer MG; Gonon F
    Neurobiol Dis; 2009 Sep; 35(3):376-84. PubMed ID: 19501163
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intrastriatal inhibition of aromatic amino acid decarboxylase prevents l-DOPA-induced dyskinesia: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine lesioned rats.
    Buck K; Ferger B
    Neurobiol Dis; 2008 Feb; 29(2):210-20. PubMed ID: 17920284
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of L-DOPA/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration.
    Pellegrini C; Antonioli L; Colucci R; Tirotta E; Gentile D; Ippolito C; Segnani C; Levandis G; Cerri S; Blandini F; Barocelli E; Ballabeni V; Bernardini N; Blandizzi C; Fornai M
    Neuropharmacology; 2017 Sep; 123():22-33. PubMed ID: 28526609
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease.
    Srinivasan J; Schmidt WJ
    Behav Brain Res; 2004 May; 151(1-2):191-9. PubMed ID: 15084435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rats with unilateral median forebrain bundle, but not striatal or nigral, lesions by the neurotoxins MPP+ or rotenone display differential sensitivity to amphetamine and apomorphine.
    Sindhu KM; Banerjee R; Senthilkumar KS; Saravanan KS; Raju BC; Rao JM; Mohanakumar KP
    Pharmacol Biochem Behav; 2006 Jun; 84(2):321-9. PubMed ID: 16820197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.
    Dekundy A; Pietraszek M; Schaefer D; Cenci MA; Danysz W
    Brain Res Bull; 2006 Apr; 69(3):318-26. PubMed ID: 16564428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.